Thanks Cato. Funny, the one thing you don't mention in that list...

Thanks Cato. Funny, the one thing you don't mention in that list of concerns (basically competition from other therapies/vaccines and potential suppply issues) is the possibility of any one or more of the three phase 3 trials failing. That would almost certainly be the first concern of any rational investor. On that matter, just about everyone here has made their own risk/reward assessment. Anyway, your views on investing basics seem to change from month to month which makes it difficult to stick to any long term strategy. Like most here I think that on a risk reward basis MSB is presenting investors with what may prove to be the opportunity of a lifetime.